Work

A phase I trial of selective PI3K inhibitor taselisib (tas) plus palbociclib (palb) with and without endocrine therapy incorporating pharmacodynamic (PD) studies in patients (pts) with advanced cancers.

Year: 2017

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2017.35.15_suppl.2573

Authors: Joline Si Jing Lim, Uzma Saddia Asghar, Nikolaos Diamantis, Sarah Emily Ward, Mona Parmar, Beth Purchase, Florence I. Raynaud, Karen E Swales, Sarah Hrebien, Emma Hall, Holly Tovey, Hannah Bye, Paula Proszek, Juanita Suzanne Lopez, Alison Joanne Turner, Johann S. De Bono, Udai Banerji, Timothy Anthony Yap, Nicholas C. Turner

Institutions: Royal Marsden Hospital, University College Hospital, Institute of Cancer Research, Royal Marsden NHS Foundation Trust

Language: English

Topic: Advanced Breast Cancer Therapies

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2781699967

Cites:

Cited by: 2

Related to: 10